Loading...
01/09 22:53
Loading...
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
The earnings call reveals significant financial challenges, including a net loss increase and zero revenue for Q1 2025, raising concerns about financial sustainability. Despite a strong cash position and potential milestone payments, extended negotiations and increased expenses further contribute to a negative outlook. The Q&A session highlighted uncertainties in regulatory progress and market entry delays. Overall, the financial struggles and uncertainties outweigh the potential positive impacts, leading to a negative sentiment rating.
EPS $-0.53 EPS, a decrease from $-0.33 EPS year-over-year.
Cash Position Approximately $144.8 million as of March 31, 2025, compared to $145 million in the previous period.
Revenue $0 for Q1 2025, a decrease of approximately $4.9 million from Q1 2024, due to the full recognition of a $40 million distribution agreement with Nippon Shinyaku in 2024.
R&D Expenses Approximately $16.2 million in Q1 2025, an increase from approximately $10.1 million in Q1 2024.
G&A Expenses Approximately $3.1 million in Q1 2025, an increase from approximately $1.8 million in Q1 2024.
Net Loss Approximately $24.4 million in Q1 2025, compared to a net loss of approximately $9.8 million in Q1 2024.
Product Approval Progress: Capricor is seeking full approval for deramiocel to treat Duchenne muscular dystrophy (DMD) cardiomyopathy, with a smooth path to FDA and a positive outlook on the BLA application.
Clinical Data Support: The BLA filing is based on the HOPE-2 study and its open-label extension, showing statistically significant differences in heart function.
New Chief Medical Officer: Dr. Michael Binks has been appointed as the new Chief Medical Officer, bringing over 25 years of experience in clinical development.
Market Expansion: Capricor is negotiating with Nippon Shinyaku for the distribution of deramiocel in Europe, with an extended negotiation period until the end of Q2 2025.
International Expansion Plans: Plans to expand the HOPE-3 trial internationally are being evaluated.
Manufacturing Capabilities: The San Diego GMP manufacturing facility is operational and producing doses of deramiocel, with an expansion planned for mid to late 2026.
Strategic Shift to Commercial Stage: Capricor is transitioning from a translational medicine company to a commercial stage entity, focusing on launch readiness for deramiocel.
Vaccine Development: The company is advancing its vaccine program under Project NextGen, with Phase 1 trials set to start in Q3 2025.
Earnings Expectations: Capricor Therapeutics missed earnings expectations with a reported EPS of $-0.53, compared to the expected $-0.33.
Regulatory Risks: Concerns were expressed regarding the FDA advisory committee meeting for Capricor, although the company views this as a positive opportunity to showcase their data.
Market Competition: Deramiocel is not designed to compete with existing therapies for dystrophinopathy, which may limit its market potential.
Supply Chain Challenges: The company is expanding its manufacturing capabilities to meet potential demand, indicating a proactive approach to supply chain management.
Financial Position: The company reported a net loss of approximately $24.4 million for Q1 2025, compared to $9.8 million in Q1 2024, raising concerns about financial sustainability.
Revenue Generation: Revenues for Q1 2025 were zero, a significant drop from $4.9 million in Q1 2024, indicating challenges in revenue generation.
Cash Runway: Capricor has a cash balance of approximately $145 million, which is projected to last until 2027 without additional cash infusions.
Partnership Risks: Negotiations with Nippon Shinyaku for European distribution have been extended, indicating potential delays in market entry.
BLA Progress: Capricor is seeking full approval for deramiocel in treating Duchenne muscular dystrophy cardiomyopathy, with a smooth path to FDA approval expected.
FDA Advisory Committee Meeting: Participation in an FDA advisory committee meeting is viewed positively, allowing Capricor to showcase strong scientific and clinical data.
Commercial Transition: Plans to transition over 100 patients from clinical to commercial product following potential BLA approval.
Manufacturing Expansion: Expansion of the San Diego GMP manufacturing facility is underway, expected to be operational mid to late 2026.
European Partnering Opportunities: Negotiations with Nippon Shinyaku for potential distribution of deramiocel in Europe are ongoing, with an extension of the negotiation period.
Exosome Program Development: Continued development of the stealth exosome platform technology as a next-generation drug delivery platform.
COVID-19 Vaccine Development: Phase 1 of the COVID-19 vaccine trial is set to start in Q3, with collaboration with NIAID.
Cash Position: Cash balance totals approximately $145 million, with a runway into 2027 without additional cash infusions.
Potential Milestone Payments: If FDA approval is received, Capricor expects an $80 million milestone payment from Nippon Shinyaku and potential total cash infusions exceeding $200 million.
Revenue Expectations: Revenues for Q1 2025 were zero, compared to $4.9 million in Q1 2024, with no current revenue sources.
Operating Expenses: R&D expenses for Q1 2025 were approximately $16.2 million, and G&A expenses were approximately $3.1 million.
Net Loss: Net loss for Q1 2025 was approximately $24.4 million, compared to a net loss of approximately $9.8 million in Q1 2024.
Cash Position: As of March 31, 2025, Capricor Therapeutics had a cash balance of approximately $145 million.
Potential Milestone Payment: If FDA approval is received, Capricor is slated to receive an $80 million milestone payment from Nippon Shinyaku.
Non-Dilutive Cash Infusions: Potential total cash infusions could exceed $200 million, including the Priority Review Voucher.
The earnings call reveals significant financial challenges, including a net loss increase and zero revenue for Q1 2025, raising concerns about financial sustainability. Despite a strong cash position and potential milestone payments, extended negotiations and increased expenses further contribute to a negative outlook. The Q&A session highlighted uncertainties in regulatory progress and market entry delays. Overall, the financial struggles and uncertainties outweigh the potential positive impacts, leading to a negative sentiment rating.
The earnings call summary presents mixed signals. The financial performance shows a significant revenue decline and increased losses, which is concerning. However, the strong cash position and potential milestone payments from a European agreement are positive. The Q&A section highlights readiness for market launch and manufacturing capabilities, but there are uncertainties in trial designs and management responses. The public offering and cash position are positive, but the revenue decline and increased expenses dampen the overall sentiment, leading to a neutral prediction with potential for positive movement if milestones are achieved.
The earnings call highlights significant progress in product development, strategic partnerships, and financial performance. Positive interim results in the Phase III trial, increased revenue, and reduced net loss are notable. The Q&A reveals confidence in regulatory strategies and strong safety profiles, despite some uncertainties. The potential for milestone payments and global expansion, along with a strong cash position, supports a positive outlook. However, increased R&D expenses and lack of specific guidance on milestone triggers and partnerships temper enthusiasm slightly. Overall, the stock is likely to see a positive movement in the short term.
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
